Question 1

What is kisspeptin?

Accepted Answer

Kisspeptin is a signaling peptide that helps start the reproductive hormone pathway. It tells the brain to release GnRH. GnRH then tells the pituitary gland to release LH and FSH. In men, LH can tell the testes to make testosterone. In women, LH and FSH help support ovulation and fertility signals.

Question 2

What is the typical kisspeptin dosage?

Accepted Answer

Typical research-context kisspeptin-10 dosing is 50-200 mcg subcutaneously, once or twice daily. Subcutaneous means under the skin. Trial-context kisspeptin-54 doses are usually written as nmol/kg, so they are harder to compare to simple mcg dosing. These are research-context numbers, not personal dosing recommendations.

Question 3

What is the difference between kisspeptin-10 and kisspeptin-54?

Accepted Answer

Kisspeptin-10 is the shorter form. Kisspeptin-54 is the longer form. Both work on the same receptor, but they do not last the same amount of time. Kisspeptin-10 has a half-life of about 4 minutes in blood after IV dosing. Kisspeptin-54 lasts longer, about 28 minutes after subcutaneous dosing. Kisspeptin-10 is usually easier to find from research suppliers.

Question 4

How is kisspeptin reconstituted?

Accepted Answer

Kisspeptin ships as a lyophilized powder. You add bacteriostatic water and gently swirl until clear. The volume you add determines the final concentration. For a 10 mg vial reconstituted with 2 mL, the final concentration is 5 mg/mL, so 2 units on a U-100 syringe equals 0.02 mL or 100 mcg. This page avoids assumptions above 3 mL because many research vials cannot hold more than that.

Question 5

What is a typical kisspeptin cycle length?

Accepted Answer

Research-context cycles are usually 2-6 weeks on, with 2-4 weeks off. Continuous, uninterrupted dosing is avoided because kisspeptin causes desensitization — the LH response fades over time when the receptor is overstimulated. A diagnostic single use (mimicking a clinical LH/FSH stimulation test or an IVF trigger) is also used in clinical settings.

Question 6

Is kisspeptin FDA-approved?

Accepted Answer

No. As of June 2026, no kisspeptin product is FDA-approved for any indication, in the U.S. or anywhere else. There is no USP, EU, or Japanese Pharmacopoeia monograph for kisspeptin-10 or kisspeptin-54. The FDA's Pharmacy Compounding Advisory Committee voted in October 2024 against adding kisspeptin-10 to the 503A Bulks List for compounding for secondary male hypogonadism.

Question 7

What are the main kisspeptin observed effects?

Accepted Answer

Reported effects from clinical trials include mild flushing, headache, short nausea, and minor injection-site irritation. The main research concern is signal fade with repeated or nonstop dosing. This is called tachyphylaxis or desensitization. The FDA also flagged animal data that may matter for heart and blood-vessel risk, but human risk is not clear.

Question 8

Can kisspeptin be used as TRT or for post-cycle therapy?

Accepted Answer

Kisspeptin is not testosterone replacement. It may raise testosterone indirectly by raising LH first, if the testes can respond. But community use for TRT, post-cycle therapy, or general hormone optimization is ahead of the human evidence. There is no completed Phase 3 trial supporting kisspeptin as a TRT alternative or PCT tool.

Question 9

What supplies are needed for a kisspeptin protocol?

Accepted Answer

A typical 4-week SC kisspeptin-10 cycle at 100 mcg daily needs one 10 mg vial, about 28 U-100 insulin syringes (0.3 mL barrel preferred), one 10 mL bottle of bacteriostatic water (you only use about 2 mL per vial), and roughly 56 alcohol swabs. Round up to allow for priming losses and any dropped or damaged supplies.

Question 10

How does kisspeptin compare to hCG?

Accepted Answer

Kisspeptin and hCG work at different levels. Kisspeptin starts higher up in the brain pathway and tries to trigger the body's own GnRH, LH, and testosterone signal. hCG acts more like LH directly at the testes or ovaries. hCG has FDA approval for IVF triggering; kisspeptin does not. In IVF research, kisspeptin-54 may have a lower OHSS risk than hCG.

Question 11

Is this kisspeptin protocol page medical advice?

Accepted Answer

No. This page is an educational research reference. It summarizes published trial protocols, research-context community planning, and FDA regulatory documents. It is not a personal dosing recommendation. Consult a licensed physician for any decisions about your own hormone status, fertility, or sexual health.

Phase	Daily reference amount	Units / volume
Weeks 1–2	100 mcg	3 units (0.03 mL)
Weeks 3–8 (or 3–12)	200 mcg	6 units (0.06 mL)

Kisspeptin.

Calculated volume reference

Cited protocol & reconstitution guide